Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes

Diabetic Medicine

Volumn 30, Issue 12, 2013, Pages 1472-1476

  Rosenstock, J ^a   Gross, J L ^b   Aguilar Salinas, C ^c   Hissa, M ^d   Berglind, N ^e,f   Ravichandran, S ^e   Fleming, D ^e  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Centro de Pesquisa Em Diabetes   (Brazil)

^c INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^d Walter Cantídio Univ Hosp   (Brazil)

^e BRISTOL MYERS SQUIBB   (United States)

^f ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; METFORMIN; METFORMIN PLUS SAXAGLIPTIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN;

ADD ON THERAPY; ARTHRALGIA; ARTICLE; BACKACHE; BRAIN HEMORRHAGE; CAUSE OF DEATH; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; LONG TERM CARE; MAJOR CLINICAL STUDY; MONOTHERAPY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PANCREATITIS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SINUSITIS; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT REDUCTION;

ADAMANTANE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84887622025     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12267     Document Type: Article

References (14)

1. Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009; 63: 1395-1406.
2. Barnett AH, Charbonnel B, Donovan M, Fleming D. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin 2012; 28: 513-523.
3. Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009; 94: 4810-4819.
4. Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009; 11: 611-622.
5. Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 376-386.
6. Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009; 25: 2401-2411.
7. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009; 32: 1649-1655.
8. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010; 64: 1619-1631.
9. Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Diabetologia 2011; 54: 243.
10. DeFronzo R, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S et al. Once-daily saxagliptin added to metformin provides sustained glycemic control and is well tolerated over 102 weeks in patients with type 2 diabetes. Diabetes 2009; 58: 547P.
11. Hollander PL, Li J, Frederich R, Allen E, Chen R; C. V. Investigators. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 2011; 8: 125-135.
12. Chacra AR, Tan GH, Ravichandran S, List J, Chen R; C. V. Investigators. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res 2011; 8: 150-159.
13. Pfützner A, Paz-Pacheco E, Allen E, Frederich B, Chen R, for the CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011; 13: 567-576.
14. Göke B, Gallwitz B, Eriksson JG, Hellqvist Å, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract 2013; 67: 307-316.